Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10549-10556
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Table 1 Average symptom relief time for patients treated with either vancomycin only or vancomycin and teicoplanin (mean ± SD)
| Vancomycin only | Vancomycin + teicoplanin | P value | |
| Patients (n) | 43 | 43 | |
| Cough and expectoration resolution (d) | 8.29 ± 2.15 | 6.12 ± 1.56 | 0.000 |
| WBC normalization (d) | 8.68 ± 2.44 | 6.77 ± 2.13 | 0.000 |
| Body temperature normalization (d) | 5.68 ± 1.18 | 4.07 ± 1.09 | 0.000 |
| Rales resolution (d) | 8.89 ± 2.02 | 6.64 ± 1.43 | 0.000 |
- Citation: Wu W, Liu M, Geng JJ, Wang M. Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections. World J Clin Cases 2021; 9(34): 10549-10556
- URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10549.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10549